Social event - Gem Room at Houston Museum of Natural Science

Thursday, February 9, 2017

7:30 AM Bus leaves hotel
7:45 AM Registration and poster set up - light breakfast
8:30 AM Oliver Bogler - Opening Remarks
8:40 AM Keynote Lecture - Patrick Hwu: "The interface between tumor biology and the anti-tumor immune response"
9:40 AM Plenary Lecture - Aartje Helland: "Predictive biomarkers for response to immunotherapy"
10:30 AM Break
11:40 AM Plenary Lecture - Sabina Naukkar: "Adoptive T cell therapy for solid tumors"
10:20 AM Coffee Break
12:30 PM Lunch
1:30 PM Workshops - breakdown by disease site: oral presentations by young investigators
5:00 PM Bus returns to hotel
6:40 PM Bus leaves hotel
7:00 PM Social event - Gem Room at Houston Museum of Natural Science
9:00 PM Bus returns to hotel

Friday, February 10, 2017

7:45 AM Bus leaves hotel
8:00 AM Light Breakfast
8:30 AM Keynote Lecture - James Allison: "Adoptive T Cell Therapy of Cancer: Personalized Medicine for Common Malignancies"
10:10 AM Coffee Break
10:30 AM Plenary Lecture - Cassian Yee: "Adoptive T Cell Therapy of Cancer: Personalized Medicine for Common Malignancies"
10:10 AM Break
12:30 PM Lunch
1:30 PM Workshops - breakdown by disease site: oral presentations by young investigators
5:00 PM Bus returns to hotel
6:10 PM Bus leaves hotel
7:00 PM Social event - George Ranch
10:00 PM Bus returns to hotel

Breakout Sessions:

Malignoma

Thursday, Feb 9

1:30 Welcome and opening remarks by session chairs
1:45 Lawrence Efron: Novel rational combination BRAF inhibition and cytokine therapy for melanoma
2:05 Carlos González: Defining immune resistance associated with melanoma and lung cancer
2:25 Jennifer Michaud: High risk mass index (BMI) is associated with improved clinical outcomes in metastatic melanoma patients treated with anti-PD1: a gender effect
2:45 Linda Judd: Regulation of immune checkpoint genes induced by a melanoma Tumor-Cancer Genome Atlas (TCGA) analysis to improve immunotherapy
3:05 Break
3:15 Alexandre Reuten: Genomic and immune heterogeneity contribute to differential responses to targeted therapy and immune checkpoint blockade in melanoma
3:35 Changlin Zhang: KMT2A promotes melanoma growth by targeting the IG5CM/ASYT1 and NFκB signaling pathways
3:55 Ageno Vincenzio: A novel non-genotoxic p53 activator reduces virus-mediated expression on melanoma cells
4:15 Gustavo Schneeman: Incidences and outcomes of central nervous system metastasis in metastatic melanoma patients treated with anti-PD1 Therapy
4:35 Anna Kuzio: NKG2D-mediated therapeutic effect of AERI101/1115 cancer vaccine in melanoma
5:00 Go to bus to return to hotel

Friday, Feb 9

1:30 Xiaogang Xu: IFNα-2b inhibitory effects on CD4+CD25+FOXP3+ regulatory T cells in the tumor microenvironment of C57BL/6 J mice with melanoma xenografts
1:50 Anna Rennhofer: Defining the activation state of melanoma antigen specific CD8+ cells as naïve/medium or effector cells
2:10 Yai Wang: Deconvolution of CFLU-labeling PD-1 blockade efficacy in B16 melanomas
3:00 Khalilah Al-Ashkar: Hassan: Use of immune checkpoint inhibition in the treatment of patients with melanoma and presenting autoimmune diseases: A systematic review of case reports
3:20 Chan-Kang Yang: Pembrolizumab Expanded Access Program (EAP) in Taiwan for patients with progressive advanced melanoma after prior ipilimumab treatment
3:40 Break
3:50 Daniel Arachchi: Prognostic relevance of baseline neutrophils and neutrophil-to-lymphocyte ratio in metastatic melanoma receiving anti-PD1 Therapy
4:10 Richard R. Lamb: Cytokine storm in patients undergoing autologous stem cell transplantation
4:30 Sang Kim: Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab while preserving the anti-tumor immunity
4:50 Wrap-up discussion
5:00 Go to bus to return to hotel

Lung

Thursday, Feb 9

1:30 Welcome and opening remarks by session chairs
1:45 Osato Favorit: Circulating miRNA in lung cancer is associated to pro-angiogenic and immunosuppressive microenvironment
2:05 Carlo Genova: Immune cell sub-populations as potential predictors of response to immunotherapy in non-small cell lung cancer
2:25 Takashi Sato: Intratumoral delivery of immuno-stimulatory oligonucleotides using biodegradable polymeric nanoparticles: effect on murine lung cancer
2:45 Yo-Ling Lai: Radiation reduces D2 related expression in TC-1 mouse lung adenocarcinoma cells
3:05 Break
3:25 Jeong Z: Cancer associated fibrillin confers resistance to anticancer drugs in lung cancer
3:45 Andrea Cattaneo: Neutrophils in advanced non-small-cell lung cancer: a comparison among different pathological criteria for assessing response
4:05 Mito Kono: Metastatic second malignancy after treatment of limited-stage small-cell lung cancer: incidence and survival
4:50 Go to bus to return to hotel

Friday, Feb 9

1:30 Jin-Liu Huang: Expression of syndecan-1 (CD138) in pulmonary lymphoplasmacytoid-like carcinoma is correlated with early stage and good prognosis
1:50 Prasanth Kudal: Upregulated expression of immune gene set associated to differentiation in women with non-small cell lung cancer
2:10 Bertha Rodriguez: PD-L1 checkpoint blockade in combination with MEK inhibition reduces lung tumor growth
2:30 Nataliya Vorobyeva: Development of a novel anti-cancer immune therapy using the synthetic oligonucleotide containing poly-G motif
2:50 Break
3:10 Llm Chen: CD8+ as a novel immune checkpoint and a mechanism of resistance to the blockade of the PD-1/PD-L1 axis
3:30 Panpan Peng: Therapeutic probe for targeted immunotherapy
3:50 Tanaya Sen: Combating immune checkpoint targeting and DNA damage repair (DDR) targeted therapy in small cell lung cancer (SCLC)
4:10 Wrap-up discussion
4:30 Go to bus to return to hotel

Lymphoma and Other

Thursday, Feb 9

1:30 Welcome and opening remarks by session chairs
1:45 Zsinó Valdés-Pérez: The potential role of CD8+ T lymphocytes in adaptive immunity and sensitivity to PD-1 blockade in diffuse large B-cell lymphoma
2:05 Liang Wang: PD-L1 is up-regulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma
2:25 Jinzhao Zhou: Dual-specific T-cell receptor gene transfer redirects T lymphocytes to display effective anti-tumor immunity
2:45 Grazio de Tullio: Development of novel immune checkpoint modulation in pancreatic adenocarcinoma
3:05 Break
3:30 Break
3:55 Break
3:35 Break
3:30 Rozana Neumann: Breast cancer immunotherapy - prospects and challenges
3:45 Fashun Chu: Dickkopf-3 (DKK3) regulates follicular cytotoxic T cells function in follicular lymphoma
4:05 Ailin Li: Role of cell shape and cell size distribution in inhibition of axonal growth in olfactory sensory neurons
4:25 Ricardo Leibowitz-Amit: Neopterin as a prognostic marker and possible target in cancer
4:50 Go to bus to return to hotel

Friday, Feb 9

1:30 Else Marit Inderberg: Tapping CD4 T cells for cancer immunotherapy
1:50 Nada Mendez: A universal killer T cell for adoptive cell therapy of cancer
2:10 Belita Zheng: HSP90 inhibitors specifically target HSP90-ACT1 and blocks T cell response
2:30 Mazeti Ryleyevski: Preclinical and clinical evidence of HSP90 as a suitable immunomodulatory target
2:50 Break
3:05 Rehia Mathur: Exploring mechanisms associated with loss from immune surveillance during early progression from smoldering multiple myeloma to symptomatic multiple myeloma
3:20 Yi Jin: Early changes in intracellular signaling network of acute myeloid leukemia in response to chemotherapy
3:45 Hila Shamir: NK cell dysfunction in CLL is associated with poor prognosis and is mediated through SHP-1
4:05 Carmen Sevintan: Assessing the suitability of standardized EuroFlow flow cytometry panels for the characterization and diagnosis of chronic lymphocytic leukemia/lymphoma (CLL/SLL) at Tygerberg Academic Hospital (TAF), South Africa
4:25 Wrap-up discussion
4:30 Go to bus to return to hotel